Skip to Content

Gadobenate dimeglumine Pregnancy and Breastfeeding Warnings

Gadobenate dimeglumine is also known as: Multihance

Medically reviewed on January 2, 2018

Gadobenate dimeglumine Pregnancy Warnings

Gadobenate dimeglumine has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadobenate dimeglumine is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Gadobenate dimeglumine Breastfeeding Warnings

There are no data on the excretion of gadobenate dimeglumine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, nursing should be discontinued prior to administration of gadobenate dimeglumine and should not be restarted until at least 24 hours after administration.

See references

References for pregnancy information

  1. "Product Information. Multihance (gadobenate dimeglumine)." Bracco Diagnostics Inc, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. Multihance (gadobenate dimeglumine)." Bracco Diagnostics Inc, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide